Join us for a virtual KOL event with Belite Bio, featuring Professor Hendrik Scholl, M.D. (Chairman of the Department of Ophthalmology, University of Basel) who will discuss the 18-month interim efficacy and safety data from Belite Bio’s Phase 2 trial evaluating tinlarebant (LBS-008) for the treatment of Stargardt disease (STGD1).

Tinlarebant is a potent, once-a-day, orally administered, small molecule RBP4 antagonist that is intended to reduce the accumulation of toxic vitamin A by-products which have been implicated in the onset and progression of STGD1 and geographic atrophy in dry age-related macular degeneration. Tinlarebant has been granted Fast Track and Rare Pediatric Disease designations in the U.S., and orphan drug designation in the U.S. and Europe for STGD1.

A live question and answer session will follow the formal presentations.